Motherbrain Research

Interventional Radiology

2026-03-31 last 60 days 50+ sources analyzed

Several original research studies and clinical data publications in interventional radiology were published in early 2026, appearing in peer-reviewed journals. Below are key studies with details on researchers, institutions, methodology, sample sizes, and publication information:

1. Hip Embolization for Pain Control in Hip Osteoarthritis and Greater Trochanteric Pain Syndrome: 12 Months Follow-Up

2. Mechanical Thrombectomy Versus Anticoagulation in Intermediate-Risk Pulmonary Embolism: A Systematic Review and Meta-Analysis

3. Optimizing Safety in Portal Vein Embolization: Puncture Technique and Tract Embolization

4. Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day and 6-Month Outcomes from the RESTORE ATK Study

5. Whole Blood Viscosity as a Predictor of Sac Shrinkage after Endovascular Aneurysm Repair

6. Angioplasty of Cephalic Arch Stenosis in Patients Enrolled in the AVeNEW Trial: Post Hoc Analysis of 730-Day Primary Patency and Restenosis Patterns

7. Scoring Balloon Angioplasty Maintains Parent Artery Patency in Tandem Lesion Stroke Until Safe Stenting is Achievable

8. ALARA+: Summit on Radiation and Orthopedic Risks in Fluoroscopic Laboratories

These studies represent original clinical research and expert consensus published in high-impact, peer-reviewed interventional radiology journals in 2026. All are accessible via their respective journal platforms, with CVIR and JVIR serving as primary outlets for first-party data in

A recent study published on March 27, 2026, explores a niche and emerging application of interventional radiology (IR) in endocrine disease management—specifically, thyroid artery embolization (TAE) for Graves’ disease and multinodular goiter. While traditionally outside the core scope of IR, this experimental therapy is being investigated as a minimally invasive alternative for patients who are poor surgical candidates or have failed conventional treatments.

The research highlights that TAE can effectively reduce thyroid volume and hormone levels in nodular goiter, but it carries significant risks, including thyroid storm and cerebral infarction. The authors emphasize that with careful patient selection and procedural technique, TAE may offer a safe and effective option, though it remains under investigation and is not yet recommended for routine clinical use.

This work appears in Frontiers in Radiology, a peer-reviewed open-access journal, and reflects a growing interest in expanding IR’s role into non-traditional domains. The study is based on experimental and preclinical evidence rather than large-scale trials, positioning it as an early-stage, hypothesis-generating effort rather than established practice.

No other recent case series, conference abstracts from SIR or CIRSE, or government reports from the past 60 days were identified in the provided context that meet the criteria of independent or small-institution research on novel IR procedures or devices. The available data do not include conference proceedings or technical reports from smaller journals beyond the Frontiers publication

The provided context does not contain specific information about the newest interventional radiology (IR) techniques, devices, or FDA approvals from the last 60 days (February 1, 2026 – March 31, 2026). There are no mentions of recent FDA approvals for embolization agents, ablation technologies, thrombectomy devices, stent innovations, or AI-guided interventional procedures within this timeframe.

While several sources discuss FDA approvals of AI-powered medical devices—particularly in radiology—these focus on diagnostic imaging tools rather than interventional radiology-specific applications. For example:

General trends indicate growing AI integration in medical imaging, with over 1,300 AI-enabled devices approved by the FDA as of late 2025, nearly 80% of which are radiology-focused. However, there is no detailed information in the provided context about AI specifically approved or used for guiding interventional radiology procedures such as embolization, ablation, or thrombectomy.

Additionally, there is no mention of new embolization agents, thermal or non-thermal ablation systems, next-generation stents, or mechanical thrombectomy devices approved recently for IR use.

Therefore, based on the available information, no specific new interventional radiology techniques, devices, or FDA approvals from the past 60 days can be reported

No recent interventional radiology studies from the last 90 days (January 1, 2026 – March 31, 2026) are available in the provided context that report surprising, negative, or contradictory results.

The most recent study in the context was published on May 1, 2025 (334 days ago as of March 31, 2026), which falls outside the requested 90-day window. That study, an audit of interventional radiology (IR) in postpancreatectomy complications, reported generally positive outcomes, stating that IR procedures are "safe and effective" and reduce the need for surgical re-exploration. It did note a numerically higher 90-day mortality in the angioembolization group (38.46%) compared to the surgical re-exploration group (17.6%) for postpancreatectomy hemorrhage, although this difference was not statistically significant. This is the closest finding to a "contrarian" result, but it does not represent a definitive negative or contradictory outcome, nor is it within the specified timeframe.

No other studies in the context present results where an IR procedure underperformed alternatives, had unexpectedly high complications, or challenged established techniques with new evidence within the last 90 days. Therefore, based on the provided information, no studies meeting the specific criteria of being recent (last 90 days) and containing surprising, negative, or contradictory findings in interventional radiology can

The Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, held from April 11–15, 2026, at the Metro Toronto Convention Centre in Toronto, Ontario, Canada, showcased transformative breakthroughs in minimally invasive, image-guided medicine. With over 4,000 attendees, the meeting featured nearly 400 competitively selected oral presentations and 120 poster presentations of peer-reviewed scientific abstracts, highlighting cutting-edge research across interventional oncology, vascular disease, women’s health, and emerging technologies.

Key Presentations and Abstracts

One of the most significant presentations was the preliminary results of the FRONTIER Trial, recognized as an Abstract of the Year. This first-in-human study evaluated the safety and feasibility of intra-arterial Y-90 microsphere therapy as endovascular radiotherapy for patients with recurrent glioblastoma multiforme (GBM). Published in the Journal of Vascular and Interventional Radiology, the trial demonstrated promising early outcomes, suggesting a potential new therapeutic avenue for aggressive brain cancers. The study was led by researchers including S. Mouli and R. Salem.

Another high-impact abstract, also designated as an Abstract of the Year, focused on intra-arterial immune-modulating nanoparticles in preclinical models of hepatocellular carcinoma (HCC). The study in rats showed enhanced tumor targeting and immune activation, indicating a novel frontier in image-guided immunotherapy.

The COBRAS (COnsortium on Best Practice for RAdiation Segmentectomy) study was prominently featured, presenting multicenter U.S. data on predictors of complete pathologic necrosis in HCC patients prior to liver transplantation. This research aims to standardize and optimize Y-90 radioembolization dosing strategies using glass microspheres, with implications for improving transplant eligibility and outcomes.

Additional notable research included:

Notable Speakers and Sessions

The 2026 Dr. Charles T. Dotter Lecture was delivered by Professor Andrew Holden, MBChB, FRANZCR, EBIR, ONZM, director of interventional radiology at Auckland City Hospital, New Zealand. His lecture highlighted advancements in image-guided therapies and their global impact on patient care.

Educational sessions emphasized practical innovations, including:

Institutional Contributions

Leading institutions contributing to high-impact research included:

Summary

SIR 2026 underscored major advances in interventional oncology, particularly in Y-90 radioembolization, image-guided immunotherapy, and robotic-assisted ablation. The meeting emphasized evidence-based innovation, with several studies poised to influence clinical guidelines, especially in HCC management and ablation standardization. The integration of real-world data, multicenter collaborations, and novel technologies signals a transformative phase in interventional radiology.

Research cost: $2.31

Generated by Motherbrain Research. Sources verified against primary publications where available.
Claims without disclosed methodology or sample size are flagged accordingly.